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INTRODUCTION
High-dose chemotherapy with stem cell rescue has been
shown to improve outcome in patients with high-risk neu-
roblastoma (NBL). In previous studies, patients who under-
went consolidation chemoradiotherapy and autologous stem
cell transplantation showed significantly higher survival than
patients who continued chemotherapy (1-5). However, more
than 50% of patients relapse after autologous peripheral blood
stem cell transplantation (APBSCT), and this is the major
cause of treatment failure in NBL. To increase survival, vari-
ous efforts have been made, such as tumor purging in the
mobilized products during stem cell mobilization, chemo-
therapy dose intensification, and various new post-transplan-
tation therapies to control minimal residual disease. Some
of the therapeutic approaches in combination with 13-cis-
retinoic acid (13-cis-RA) have shown promising results in
terms of survival improvement. On the other hand, some
widely used treatment modalities, such as tandem transplan-
tation and IL-2 therapy, are still controversial.
In this study, we analyzed the clinical features and outcomes
of stage III and IV NBL patients who underwent APBSCT
at Seoul National University Children’s Hospital (SNUCH).
Survival was analyzed according to the APBSCT type, espe-
cially with respect to the effect of CD34+ selection and trans-
plantation number on survival. Various other prognostic fac-
tors, such as age, primary mass location, bone marrow metas-
tasis, and pre-transplantation disease status, were also analyzed. 
MATERIALS AND METHODS
Patients
A retrospective analysis was performed on 36 NBL patients
who underwent APBSCT between May 1996 and May 2004.
Patients were allocated to three groups according to the AP-
BSCT type, i.e., to the CD34+ nonselected single APBSCT
group (13 patients; the nonselected single group), the CD34+
selected single APBSCT group (14 patients; the selected
single group), and to the CD34+ selected double APBSCT
group (9 patients; the selected double group). One patient
in the selected single group underwent APBSCT twice, be-
fore and after relapse, and thus 46 transplants were performed
in 36 patients. A detailed review of clinical data was perform-
ed to ascertain the age at diagnosis, sex, tumor location, extent
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Retrospective Analysis of Peripheral Blood Stem Cell Transplantation
for the Treatment of High-Risk Neuroblastoma
Disease relapse after autologous peripheral blood stem cell transplantation (APB-
SCT) is the main cause of treatment failure in high-risk neuroblastoma (NBL). To
reduce relapse, various efforts have been made such as CD34
+ selection and dou-
ble APBSCT. Here the authors reviewed the clinical features and outcomes of high-
risk NBL patients and analyzed their survival. The medical records of 36 patients
with stage III or IV NBL who underwent APBSCT at Seoul National University Chil-
dren’s Hospital between May 1996 and May 2004 were reviewed. Total 46 APB-
SCTs were performed in 36 patients. Disease free survival (DFS) and overall sur-
vival of all patients were 47.7% and 68.8%, respectively. The patients were allocat-
ed to three groups according to the APBSCT type. The DFS of CD34
+ non-select-
ed single APBSCT patients (N=13), CD34
+ selected single APBSCT patients (N=
14), and CD34
+ selected double APBSCT patients (N=9) were 55.6%, 40.6%, and
50.0%, respectively, which were not significantly different. Thus the survival was
not found to be affected by CD34
+ selection or transplantation number. To improve
long-term survival, various efforts should be made such as chemotherapy dose
intensification, more effective tumor purging, and control of minimal residual dis-
ease via the use of differentiating and immune-modulating agents. 
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of tumor, stage, N-myc gene copy number, disease status at
transplantation, number of APBSCTs, CD34+ selection, con-
ditioning regimen, number of cells infused, hematopoietic
reconstitution, post-transplantation complications, post-trans-
plantation therapy, and outcome.
Pre-transplantation treatment 
All patients received chemotherapy before APBSCT. After
4 or 5 cycles of chemotherapy, debulking operation was per-
formed and local radiotherapy and chemotherapy followed.
The CCG-321-P2 chemotherapy regimen (6) was used in
nearly all patients, which consisted of cisplatin, VP-16, dox-
orubicin, and cyclophosphamide.
Stem cell collection and CD34
+ selection
To mobilize stem cells, 10  g/kg of G-CSF was injected
subcutaneously (s.c.) from 7 days after the start of mobiliza-
tion chemotherapy, which consisted of 1,000 mg/m2 cyclo-
phosphamide and 150 mg/m2 etoposide on days 0, 1, and 2,
until the last day of peripheral blood stem cell (PBSC) collec-
tion. PBSC collection began from the day when the WBC co-
unt exceeded 1,000/ L after a nadir and was continued for 2
or 3 days to obtain ≥6×108/kg of mononuclear cells (MNCs).
In most patients stem cells were collected by apheresis, and
bone marrow harvest and apheresis were combined in two
APBSCTs. Leukapheresis was performed using CS-3000 Plus
(Baxter Healthcare, Deerfield, IL, U.S.A.) or COBE Spectra
(COBE Laboratories, Lakewood, CO, U.S.A.). In 23 of 36
patients, CD34+ selection was performed using a CliniMACS
(Miltenyi Biotec, Bergisch Gladbach, Germany) device to
purge tumor cells from mobilized PBSCs. 
Conditioning regimen
Various conditioning regimens were used and are summa-
rized in Table 1. The main conditioning regimen was the
MEC regimen, which consisted of carboplatin 400 mg/m2 on
days -8 to -5, etoposide 200 mg/m2 on days -8 to -5, mel-
phalan 140 mg/m2 on day -7 and 70 mg/m2 on day -6. This
regimen was used in 30 transplants. Total body irradiation
(TBI) was not performed in any case of APBSCT. 
Post-transplantation treatment
All patients received interleukin-2 (IL-2; aldesleukin; Pro-
leukin, Chiron, Emeryville, CA, U.S.A.) and 13-cis-RA. Re-
combinant IL-2 at 3×106 IU/m2 was delivered s.c. once daily
for 5 consecutive days every other week for 11 weeks (total
30 doses), starting when the absolute neutrophil count (ANC)
and the platelet count exceeded 1,000/ L and 50,000/ L,
respectively. Patients began to receive 13-cis-RA 100 mg/m2
once daily 28 days after APBSCT, and this was maintained
for 1 yr.
Statistical analysis
The numbers of CD34+ cells infused in two groups were
compared using the Mann-Whitney test. The correlation
between infused cell doses and hematopoietic reconstitution
was analyzed using Pearson’s correlation coefficients. Dis-
ease-free survival (DFS) and overall survival (OS) were esti-
mated using the Kaplan-Meier curves, and the curves were
compared using the log-rank test. Statistical significance
was accepted at the p<0.05 level.
RESULTS
Patient characteristics
The enrolled patients consisted of 25 males and 11 females
with a median age at diagnosis of 3 yr (7 months-10 yr 1
month). Five patients were less than 1 yr old. The N-myc
gene amplification test was performed in 11 patients, and 5
patients demonstrated amplification. Of 5 patients, 1 patient
belonged to the nonselected group, 3 to the selected single
group, and 1 patient to the selected double group. Thirty
four patients were in stage IV NBL, and only 2 patients were
in stage III NBL. To reduce tumor cell contamination, CD34+
selection was performed in 23 patients. In case who under-
went double APBSCT, PBSCs were collected before the first
transplantation. The median time from diagnosis to trans-
plantation was 10 months (5-46 months), and the median
time between the 1st and 2nd transplantation was 3 months
(2-3 months). The median follow-up durations from diag-
nosis and from APBSCT were 42 months (11-103 months)
and 27 months (1-93 months), respectively. Patient charac-
teristics are summarized in Table 2.
No. of transplants
CD34
+ selection
Selected product infusion 30
Nonselected product infusion 14
Mixed infusion 2
No. of transplantation
Single 26
Double 9
Twice (before and after relapse) 1
Conditioning regimen
Melphalan, Etoposide, Carboplatin 30
Topotecan, Thiotepa, Carboplatin 10
Melphalan, Etoposide 3
Topotecan, Melphalan, Carboplatin 3
Table 1. CD34
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Hematopoietic reconstitution and post-transplantation
complications
Of the 46 transplants, CD34+ selected products were used
in 30 transplants, and nonselected products were used in 14.
In 2 transplants, selected and nonselected mobilized products
were infused together, and thus, the analyses concerning the
number of cells infused and hematopoietic reconstitution did
not include these two transplants. However, in the survival
analysis, one of these patients was included in the selected
single group because most cells infused were collected by
CD34+ selected mobilization. The other patient was includ-
ed in the selected double group because half of the cells in-
fused in the 1st transplantation and all cells infused in the
2nd transplantation were collected by CD34+ selected mobi-
lization, although selected and nonselected products were
infused together in the 1st transplantation. After selection,
the mean purity of the CD34+ cell fraction was 92.4% (81.4-
99.5%).
In CD34+ selected and nonselected transplants, the medi-
an doses of CD34+ cells infused were 4.4×106/kg (0.9-45.8
×106/kg) and 14.9×106/kg (3.8-77.1×106/kg), respec-
tively, and the CD34+ cell dose was significantly higher in the
nonselected group (p=0.001). In selected transplants, the me-
dian number of days required for an ANC higher than 500/
L, or 1,000/ L and a platelet count of higher than 20,000/
L were 11 days (8-20 days), 12 days (9-25 days), and 17
days (10-219 days), respectively. In nonselected transplants,
the median number of days required for the same conditions
were 11 days (8-15 days), 11 days (8-16 days), and 18 days
(8-99 days), respectively. In 3 patients who belonged to the
CD34+ selected group, platelet recovery of more than 20,000/
L was not achieved until 100 days after APBSCT. No sig-
nificant difference was found between the CD34+ selected
and nonselected groups, in terms of the number of days re-
quired for hematopoietic reconstitution, and infused CD34+
cell doses were not found to be related to hematopoietic recon-
stitution (p>0.1).
After APBSCT, fever developed in all patients, and venooc-
clusive disease or hemorrhagic complication (gastroinfesti-
nal weeding or pulmonary hemorrhage) occurred in 7 and 5
patients, respectively. One patient died of disease progres-
sion before the 2nd scheduled APBSCT, and 2 patients died
of treatment-related conditions, i.e., acute renal failure and
pulmonary hemorrhage in both cases. Most patients experi-
enced vomiting, diarrhea, and oral mucositis. 
Treatment outcome
DFS and OS values for all patients were 47.7±9.6% and
68.8±9.1%, respectively (Fig. 1). The DFSs of the nonse-
lected single, the selected single, and the selected double
groups were 55.6±14.9%, 40.6±14.7%, and 50.0±20.4
%, respectively (Fig. 2A), and OSs of the three groups were
92.3±7.4%, 55.1±13.9%, and 66.7±19.3%, respectively,
none of which were significantly different between the three
groups. When all patients were dichotomized according to
CD34+ selection (selection N=23, nonselection N=13), the
DFSs of the selected and nonselected groups were 42.6±12.4
% and 55.6±14.9%, respectively (Fig. 2B), and the relapse
rates of these two groups were not significantly different (p=
Age at diagnosis
<1 yr 5
≥1 yr 31
Sex
Male 25
Female 11
Primary site
Abdominal mass 32
Extra-abdominal mass* 4
N-myc amplification status
Single 6
Amplification 5
Not checked 25
Metastatic sites at diagnosis
Bone marrow 29
Bone 29
Bone marrow & bone 27
Tumor stage
Stage III (with residual disease) 2
Stage IV 34
Pre-transplantation disease status
Complete response 10
Partial response 26
CD34
+ cell selection
Selection 23
Non-selection 13
Table 2. Patient characteristics (N=36)
*Extra-abdominal mass included maxillary sinus and mediastinum.
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Fig. 1. Kaplan-Meier probabilities of DFS and OS for high-risk
neuroblastoma patients after APBSCT (N=36). DFS was 47.7±
9.6% and OS 68.8±9.1%. Ticks indicate censored data.
DFS, disease-free survival; OS, overall survival; APBSCT, autolo-
gous peripheral blood stem cell transplantation; PBSCT, periph-
eral blood stem cell transplantation.Treatment of High-Risk Neuroblastoma S69
0.536).
Various prognostic factors likely to influence DFS were
analyzed. Patients younger than 1 yr had a better prognosis
than older patients (p=0.041), but prognosis was not signif-
icantly affected by the primary mass location, bone marrow
metastasis, or pre-transplantation disease status. Moreover,
the DFS of patients who underwent double APBSCT was
similar to that of patients who underwent single APBSCT
(p=0.499).
DISCUSSION
High-dose chemotherapy with APBSCT has improved the
survival of high-risk NBL patients over past decades. How-
ever, a large number of patients relapse after APBSCT despite
having a complete remission disease status before APBSCT
(7-9). Reinfused tumor cells are believed to play an impor-
tant role in relapse, particularly in patients with no detectable
systemic residual disease (10-13). Moreover, increasing num-
bers of studies show that up to 50% of bone marrow and PBSC
harvests from patients with bone marrow remission contain
tumor cells (1, 14, 15). Because NBL cell contamination of
infused PBSCs is strongly correlated with relapse risk after
APBSCT, effective tumor purging is essential to improve
survival in the high-risk NBL. The most widely used purg-
ing method is based on selection for CD34 antigen, which
is expressed on hematopoietic stem cells. In many studies,
2-4 logs of tumor cell removal was observed after CD34+selec-
tion (14, 16-18). This method has been generally used in NBL
patients because NBL cells are believed not to express CD34
antigen. However, Hafer et al. revealed that some NBL cell
lines do express CD34 antigen and recommended that cau-
tion should be taken with transplants obtained by CD34+
selection (19). In addition, EFS was not found to be statisti-
cally different between CD34+ selected and nonselected pa-
tients in some reports (4, 7, 8). In the present study, the DFSs
of CD34+ selected and nonselected groups were not statisti-
cally different (p=0.536). Randomized large-scale clinical
trials are required to defermine whether NBL patient sur-
vival rates can be increased by CD34+ selection, and a more
effective tumor purging method is required to prevent the
tumor contamination of mobilized products. 
Chemotherapy dose is also intensified to reduce relapse.
Today, myeloablative therapy has become the standard treat-
ment for high-risk NBL since the Children’s Cancer Group
reported the result of a randomized trial which compared mye-
loablative therapy and autologous bone marrow transplan-
tation with chemotherapy alone (2). Three-year event-free
survival (EFS) was found to be significantly better in patients
randomized to the transplantation arm than in patients ran-
domized to continuous chemotherapy alone (34±4% vs.
22±4%, respectively; p=0.034). Moreover, the suggestion
that high doses of chemotherapy might improve OS in pa-
tients with high-risk NBL has led some investigators to ex-
plore tandem transplantation, which is a novel way of increas-
ing dose intensity for the treatment of chemosensitive tumors.
The theoretical advantages of this include the exposure of
tumors to multiple effective agents at maximum-tolerated
doses and the possible modulation of the tumor microenvi-
ronment during the first transplantation, thus potentiating
cell killing during the second transplantation (20). Tandem
transplantation has been studied mainly in adults with breast
cancer, lymphoma, and multiple myeloma (21-23), and few
studies have been conducted in children. The earliest work
used a double harvest/double graft approach with purged
Fig. 2. DFSs of patients according to (A) the type of APBSCT and (B) CD34
+ selection. Survival curves indicated no statistical differences
between the various groups. Ticks indicate censored data. 
DFS, disease-free survival; APBSCT, autologous peripheral blood stem cell transplantation; PBSCT, peripheral blood stem cell transplanta-
tion.
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autologous bone marrow support (24). In this study, OS was
encouraging, but when bone marrow was used for stem cell
support, delayed engraftment and a high toxic death rate
after the second graft were identified as potential major prob-
lems. In 2000, Grupp et al. first reported the results of tan-
dem transplantation using PBSC in a pediatric cohort (20).
Thirty-three high-risk NBL patients completed two myelo-
ablative therapies with stem cell rescue and achieved a 3-yr
EFS of 58%. These investigators demonstrated that PBSC-
supported tandem transplantation in high-risk NBL is fea-
sible with acceptable toxicity and adequate hematopoietic
recovery. Subsequently, several investigators found that PBSC-
supported double/triple tandem cycles of high-dose chemo-
therapy achieved higher EFS than single transplantation (4,
25, 26). Nevertheless, 3- and 5-yr EFSs were still below 60%.
According to our results, DFS is not dependent on the num-
ber of transplantations. However, whether tandem (double
or triple) transplantations with PBSC support have an impact
on long-term EFS in high-risk NBL remains controversial.
A phase III randomized study on the effect of tandem trans-
plantation with PBSC rescue in patients with high-risk NBL
is currently under way by the Children’s Oncology Group.
The eradication of minimal residual disease by post-trans-
plantation therapy is now considered important for the im-
provement of survival in the high-risk NBL. Various post-
transplantation therapies have been used including IL-2 and
13-cis-RA (isotretinoin), the latter of which is derived from
naturally occurring all-trans-retinoic acid (ATRA) by termi-
nal carboxyl group modification. When NBL cell lines were
exposed to 13-cis-RA in vitro, it was found to decrease pro-
liferation and N-myc oncogene expression, and to induce the
morphologic differentiation of tumor cells (27-29). In 1995,
a phase I study of children with high-risk NBL showed that
13-cis-RA administered after bone marrow transplantation
had minimal toxicity and that it cleared NBL cells from bone
marrow (30). In 1999, a nationwide phase III trial (CCG-
3891) was conducted, and found that the 3-yr EFS was sig-
nificantly better in patients who received 13-cis-RA after
transplantation than in those who did not (46±6% vs. 29
±5%, p=0.027) (2). Moreover, the effect of 13-cis-RA was
found to be the most pronounced in a setting of truly mini-
mal residual disease because the positive benefit of 13-cis-RA
was not evident in children with histologically proven residu-
al disease. Today, maintenance therapy with 13-cis-RA after
myeloablative therapy has become a standard part of high-
risk NBL therapy.
Immune system modulation to stimulate an antitumor
response is considered a therapeutic alternative, and the potent
immunostimulatory cytokine IL-2 has been investigated in
this context in a number of tumor models (31, 32). In some
clinical trials, an antitumor effect has been demonstrated in
children with NBL (33-35), but the effect of IL-2 remains
controversial (36, 37). Further studies are needed before IL-
2 is widely used as a standard post-transplantation therapy.
In conclusion, although significant survival improvements
have been observed in high-risk NBL patients, high relapse
rates after transplantation remain a challenge. It is evident
that more complete local tumor control is essential to reduce
relapse rates, and that more aggressive surgical resection fol-
lowed by more intensive chemotherapy is needed. In addi-
tion, the effectiveness of tandem transplantation should be
confirmed using intensified regimens with tolerable toxici-
ties. During mobilization, much effort should be made to
reduce tumor contamination. It is important to develop a
more effective tumor purging method as well as to confirm
the effectiveness of CD34+ selection. In addition, the con-
trol of minimal residual disease after transplantation may
contribute substantially to long-term survival. Drugs that
accelerate NBL cell differentiation and modulate immune
response should be developed, and various approaches to im-
prove survival are possible by adopting pre- and post-trans-
plantation therapies. Our study is limited because the num-
ber of patients was small, and risk factors, such as N-myc gene
copy number, were not thoroughly examined, which made
it difficult to evaluate the true effect of the type of APBSCT
on survival. However, it does provide a worthwhile compar-
ison of the survival rates of various treatment cohorts accord-
ing to the type of APBSCT. A prospective study involving a
larger population would provide a better overview of the com-
parative effects of treatment modalities. 
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